Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Enterprise Value: 2012-2025

Historic Enterprise Value for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $67.0 million.

  • Enanta Pharmaceuticals' Enterprise Value rose 333.78% to $67.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$547.1 million, marking a year-over-year increase of 38.95%. This contributed to the annual value of $67.0 million for FY2025, which is 333.78% up from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Enterprise Value is $67.0 million, which was up 257.70% from -$42.5 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Enterprise Value ranged from a high of $1.3 billion in Q4 2021 and a low of -$139.0 million during Q4 2023.
  • In the last 3 years, Enanta Pharmaceuticals' Enterprise Value had a median value of -$28.7 million in 2024 and averaged $33.1 million.
  • Over the last 5 years, Enanta Pharmaceuticals' Enterprise Value had its largest YoY gain of 333.78% in 2025, and its largest YoY loss of 209.48% in 2025.
  • Enanta Pharmaceuticals' Enterprise Value (Quarterly) stood at $1.3 billion in 2021, then plummeted by 40.28% to $753.0 million in 2022, then crashed by 118.46% to -$139.0 million in 2023, then soared by 31.77% to -$94.8 million in 2024, then spiked by 333.78% to $67.0 million in 2025.
  • Its Enterprise Value stands at $67.0 million for Q3 2025, versus -$42.5 million for Q2 2025 and -$75.6 million for Q1 2025.